Diagnosis, clinical characteristics, and treatment of combined hepatocellular-cholangiocarcinoma

被引:0
|
作者
Terashima, Takeshi [1 ]
Harada, Kenichi [2 ]
Yamashita, Taro [1 ]
机构
[1] Kanazawa Univ Hosp, Dept Gastroenterol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan
[2] Kanazawa Univ, Dept Human Pathol, Grad Sch Med Sci, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan
关键词
combined hepatocellular-cholangiocarcinoma; systemic therapy; immunotherapy; PLATINUM-BASED CHEMOTHERAPY; CARCINOMA; FEATURES; HEPATOCHOLANGIOCARCINOMA; CT;
D O I
10.1093/jjco/hyaf029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The concept and definition of combined hepatocellular-cholangiocarcinoma (cHCC-CCA), an extremely rare condition accounting for only 1% of all primary liver cancers, has shifted in recent years. The latest World Health Organization Classification (fifth edition) includes two types of cHCC-CCAs, (i) the classical type described in the previous edition, which contains a mixture of distinctly differentiated components of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) and (ii) intermediate cell carcinoma wherein all cells comprising the tumor express both hepatocellular and cholangiocellular features. However, the pathogenesis of cHCC-CCA, including its origins, remains controversial even among experts. Treatment strategies for cHCC-CCA in clinical practice have been determined based on imaging findings, tumor markers, and pathologically predominant tumor components for either HCC or ICC, suggesting that cHCC-CCA has yet to be been established as an independent disease entity. As with HCC and ICC, the treatment strategy for HCC-CCA involves initially considering resectability. Although systemic therapy has been considered for patients unsuitable for local treatment, no prospective clinical trials have evaluated the efficacy and safety of systemic therapy for cHCC-CCA, which could explain the lack of a standard of care. In recent years, however, studies have demonstrated the efficacy of immune checkpoint inhibitors for HCC and ICC, with therapeutic results having been reported for cHCC-CCA. Hence, further accumulation of cases is expected to facilitate the establishment of a consensus on treatment strategies in the near future. The WHO Classification includes a definition for combined hepatocellular-cholangiocarcinoma. Treatment strategies are determined according to either hepatocellular carcinoma or intrahepatic cholangiocarcinoma considering tumor markers or radiological and pathological findings.
引用
收藏
页码:327 / 333
页数:7
相关论文
共 50 条
  • [41] A HISTOCHEMICAL-STUDY ON COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA
    UEKUSA, T
    MASTUMOTO, T
    ABE, H
    FUKUDA, Y
    ACTA HISTOCHEMICA ET CYTOCHEMICA, 1987, 20 (06) : 737 - 737
  • [42] Co-occurrence of hepatocellular carcinoma and combined hepatocellular-cholangiocarcinoma
    Suren, D.
    Yildirim, M.
    INDIAN JOURNAL OF CANCER, 2015, 52 (04) : 622 - +
  • [43] The Dominant Component and Clinicopathological Characteristics of Combined Hepatocellular-cholangiocarcinoma After Radical Resection
    Matsubara, Keiso
    Kobayashi, Tsuyoshi
    Tadokoro, Takeshi
    Namba, Yosuke
    Fukuhara, Sotaro
    Oshita, Ko
    Honmyo, Naruhiko
    Kuroda, Shintaro
    Arihiro, Koji
    Ohdan, Hideki
    ANTICANCER RESEARCH, 2024, 44 (10) : 4551 - 4559
  • [44] Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma
    Jang, Yoon Jung
    Kim, Eo Jin
    Kim, Hyung-Don
    Kim, Kyu-Pyo
    Ryu, Min-Hee
    Park, Sook Ryun
    Choi, Won-Mook
    Lee, Danbi
    Choi, Jonggi
    Shim, Ju Hyun
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    Ryoo, Baek-Yeol
    Yoo, Changhoon
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (10) : 7547 - 7555
  • [45] Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers
    Wakizaka, Kazuki
    Yokoo, Hideki
    Kamiyama, Toshiya
    Ohira, Masafumi
    Kato, Koichi
    Fujii, Yuki
    Sugiyama, Ko
    Okada, Naoki
    Ohata, Takanori
    Nagatsu, Akihisa
    Shimada, Shingo
    Orimo, Tatsuya
    Kamachi, Hirofumi
    Taketomi, Akinobu
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (06) : 1074 - 1080
  • [46] Clinical Significance of ACYP1 Gene Expression in Combined Hepatocellular-Cholangiocarcinoma
    Sakano, Yoshihiro
    Noda, Takehiro
    Kobayashi, Shogo
    Iwagami, Yoshifumi
    Tomimaru, Yoshito
    Akita, Hirofumi
    Gotoh, Kunihito
    Umeshita, Koji
    Doki, Yuichiro
    Eguchi, Hidetoshi
    CANCER SCIENCE, 2021, 112 : 805 - 805
  • [47] Update on the Diagnosis and Treatment of Combined Hepatocellular Cholangiocarcinoma
    Chu, Kai-Jian
    Kawaguchi, Yoshikuni
    Wang, Han
    Jiang, Xiao-Qing
    Hasegawa, Kiyoshi
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2024, 12 (02) : 210 - 217
  • [48] Patients' prognosis of intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma after resection
    Song, Peipei
    Midorikawa, Yutaka
    Nakayama, Hisashi
    Higaki, Tokio
    Moriguchi, Masamichi
    Aramaki, Osamu
    Yamazaki, Shintaro
    Aoki, Masaru
    Teramoto, Kenichi
    Takayama, Tadatoshi
    CANCER MEDICINE, 2019, 8 (13): : 5862 - 5871
  • [49] Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinoma
    Kim, Eo Jin
    Yoo, Changhoon
    Kang, Hyo Jeong
    Kim, Kyu-Pyo
    Ryu, Min-Hee
    Park, Sook Ryun
    Lee, Danbi
    Choi, Jonggi
    Shim, Ju Hyun
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    Ryoo, Baek-Yeol
    LIVER INTERNATIONAL, 2021, 41 (06) : 1398 - 1408
  • [50] Clinical and pathological analysis of 27 patients with combined hepatocellular-cholangiocarcinoma in an Asian center
    Zhan, Qian
    Shen, Bai-Yong
    Deng, Xia-Xing
    Zhu, Zhe-Cheng
    Chen, Hao
    Peng, Chen-Hong
    Li, Hong-Wei
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2012, 19 (04) : 361 - 369